Postoperative recurrence pattern and prognosis of patients with hepatocellular carcinoma, with particular reference to the hepatitis viral infection status

2014 ◽  
Vol 34 (5) ◽  
pp. 802-813 ◽  
Author(s):  
Shigetoshi Naito ◽  
Hiroshi Imamura ◽  
Akira Tukada ◽  
Yutaka Matsuyama ◽  
Jiro Yoshimoto ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Infection ◽  
Postoperative Recurrence ◽  
Recurrence Pattern ◽  
Infection Status ◽  
Viral Infection Status

scholarly journals IgM Antibody Repertoire Fingerprints in Mice Are Personalized but Robust to Viral Infection Status

2020 ◽  
Vol 10 ◽  
Author(s):  
Alexander Yermanos ◽  
Nike Julia Kräutler ◽  
Alessandro Pedrioli ◽  
Ulrike Menzel ◽  
Victor Greiff ◽  
...  
Keyword(s):  
Viral Infection ◽  
Antibody Repertoire ◽  
Infection Status ◽  
Igm Antibody ◽  
Viral Infection Status

Understanding ‘risk’ in families living with mixed blood-borne viral infection status: The doing and undoing of ‘difference’

2020 ◽  
pp. 136345932094646
Author(s):  
Asha Persson ◽  
Anthony KJ Smith ◽  
Jack Wallace ◽  
kylie valentine ◽  
Joanne Bryant ◽  
...  
Keyword(s):  
Viral Infection ◽  
Viral Hepatitis ◽  
Family Relationships ◽  
Viral Infections ◽  
Qualitative Interviews ◽  
Transmission Risk ◽  
Infection Status ◽  
Mary Douglas ◽  
The Family ◽  
Viral Infection Status

‘Risk’ has long been at the centre of expert and popular perceptions of transmissible and stigmatised blood-borne viral infections, such as HIV and viral hepatitis. There is a substantial body of research on transmission risk among couples with mixed viral infection status (serodiscordance). But we know very little about how families affected by HIV and viral hepatitis engage with understandings of infectiousness and how these shape family relationships in different ways. Guided by cultural theories of risk that build on Mary Douglas’ work, we draw on qualitative interviews to explore the ‘performativity’ of risk in serodiscordant families in Australia. We show how the ‘doing’ of risk could be constitutive of difference, which unsettled the family connection or deepened existing fault lines. Conversely, the ‘undoing’ of risk enabled the preservation of the family bond by rejecting difference and reframing risk as an external threat to the family in the form of stigma. We conclude that risk in the context of serodiscordant families had relational implications far beyond viral transmission and consider what our findings might mean for service provision and health promotion campaigns related to blood-borne viruses.

scholarly journals The Role of Endoglin in Hepatocellular Carcinoma

2021 ◽  
Vol 22 (6) ◽  
pp. 3208
Author(s):  
Kuo-Shyang Jeng ◽  
I-Shyan Sheen ◽  
Shu-Sheng Lin ◽  
Chuen-Miin Leu ◽  
Chiung-Fang Chang
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Diseases ◽  
Transforming Growth Factor ◽  
Antiangiogenic Therapy ◽  
Transforming Growth Factor Β ◽  
Postoperative Recurrence ◽  
Transmembrane Glycoprotein ◽  
Early Progression

Endoglin (CD105) is a type-1 integral transmembrane glycoprotein and coreceptor for transforming growth factor-β (TGF-β) ligands. The endoglin/TGF-β signaling pathway regulates hemostasis, cell proliferation/migration, extracellular matrix (ECM) synthesis and angiogenesis. Angiogenesis contributes to early progression, invasion, postoperative recurrence, and metastasis in hepatocellular carcinoma (HCC), one of the most widespread malignancies globally. Endoglin is overexpressed in newly formed HCC microvessels. It increases microvessel density in cirrhotic and regenerative HCC nodules. In addition, circulating endoglin is present in HCC patients, suggesting potential for use as a diagnostic or prognostic factor. HCC angiogenesis is dynamic and endoglin expression varies by stage. TRC105 (carotuximab) is an antibody against endoglin, and three of its clinical trials were related to liver diseases. A partial response was achieved when combining TRC105 with sorafenib. Although antiangiogenic therapy still carries some risks, combination therapy with endoglin inhibitors or other targeted therapies holds promise.

Risk factors for postoperative recurrence of non-B non-C hepatocellular carcinoma

2009 ◽  
Vol 17 (3) ◽  
pp. 291-295 ◽  
Author(s):  
Hiroji Shinkawa ◽  
Takahiro Uenishi ◽  
Shigekazu Takemura ◽  
Kazuki Ohba ◽  
Masao Ogawa ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Postoperative Recurrence
Sign in / Sign up

Export Citation Format

Share Document